It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Surgical site infections and antimicrobial resistance remain major challenges globally
A key highlight will be Brenntag’s qualified amino acids portfolio
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
The collaboration aims to make Alzheimer’s biomarker testing more accessible and less intimidating
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
Subscribe To Our Newsletter & Stay Updated
